Clinical Trial Detail

NCT ID NCT02584309
Title Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Washington University School of Medicine
Indications

angiosarcoma

malignant peripheral nerve sheath tumor

malignant fibroxanthoma

leiomyosarcoma

epithelioid sarcoma

sarcoma

fibrosarcoma

synovial sarcoma

Therapies

dexrazoxane

Doxorubicin + Olaratumab

Age Groups: senior adult

No variant requirements are available.